Twist Bioscience Exceeds Q4 Earnings and Revenue Estimates, Issues Strong Fiscal 2027 Guidance
Twist Bioscience (TWST) reported fourth-quarter financial results that surpassed both top-line and bottom-line analyst expectations. The company posted GAAP earnings per share of -$0.32, beating estimates by $0.06, while revenue reached $126.6 million, representing a 27.9% increase year-over-year and exceeding consensus by approximately $2.97 million. Looking ahead, the company provided optimistic guidance for fiscal year 2027, projecting revenue between $550 million and $560 million. This forecast sits above the market consensus of $548.67 million and implies a midpoint growth rate of approximately 21% year-over-year, signaling sustained momentum in its synthetic biology operations.
Tickers: $TWST
Topics: earnings beat financial guidance revenue growth
Read the full article at Seeking Alpha
Part of the story TransDigm Issues Fiscal 2027 Revenue Guidance and Outlines M&A Strategy (5 articles)